Phase 3 Ovarian Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed by biopsy to have low-grade serous ovarian, fallopian tube, or peritoneal cancer (LGSOC)
• People whose tumour has been tested for a gene change called KRAS, using an approved tumour tissue test
• People whose cancer has come back or gotten worse after at least one previous systemic (whole-body) cancer treatment
• People for whom a doctor has determined at least one of the following treatments is suitable: pegylated liposomal doxorubicin, paclitaxel, letrozole, or anastrozole
• People whose cancer can be measured on scans using standard criteria (called RECIST v1.1)
• People who are largely able to care for themselves and carry out light activities (a performance score of 0 or 1 on a standard medical scale)
• People whose liver, kidneys, and other organs are functioning well enough
• People who have recovered sufficiently from side effects of any previous cancer treatments
• People of reproductive potential who have had a negative pregnancy test and agree to use a highly effective form of contraception during the trial
• People who are willing and able to attend scheduled visits, follow the treatment plan, and complete all required tests and procedures

Who may not be able to join:

• People who have received systemic cancer treatment within 4 weeks before the first dose of the trial treatment
• People who have both low-grade and high-grade ovarian cancer, or a mixed type of ovarian cancer
• People who have previously been treated with avutometinib, defactinib, or any other FAK inhibitor drug
• People who have had another cancer that came back within the last 3 years
• People who have had major surgery within 4 weeks, minor surgery within 1 week, or palliative radiotherapy within 1 week before the first trial dose
• People with brain metastases causing symptoms that require steroids or other treatments, or who have cancer spread to the membranes around the brain or spinal cord
• People who have had a skin condition requiring systemic (whole-body) treatment within the past year
• People with a significant history of a serious muscle-breakdown condition called rhabdomyolysis
• People who previously received certain targeted therapies (MEK or RAF inhibitors) and experienced a severe (Grade 4) toxic reaction related to those drugs
• People who had a symptomatic bowel blockage within 3 months before the first trial dose
• People with current eye disorders
• People with current heart disease or severe lung disease affecting breathing
• People with a history of inflammatory lung conditions, including drug- or radiation-related lung inflammation, lung scarring, or severe respiratory distress
• People who are unable to swallow oral (by mouth) medications
• People with a known allergy or sensitivity to any ingredients in the trial treatments, including peanut, soy, or polyoxyl castor oil; or a prior allergic reaction to anthracycline-type drugs if pegylated liposomal doxorubicin is planned for use
• People who are pregnant or breastfeeding
• People with an active, uncontrolled infection (bacterial, viral, or fungal) that requires systemic treatment

Important: Always verify eligibility with the trial site directly before applying.